1465 related articles for article (PubMed ID: 12538684)
21. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
[TBL] [Abstract][Full Text] [Related]
22. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
23. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
24. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.
Schreiner B; Bailey SL; Shin T; Chen L; Miller SD
Eur J Immunol; 2008 Oct; 38(10):2706-17. PubMed ID: 18825752
[TBL] [Abstract][Full Text] [Related]
25. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
26. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
[TBL] [Abstract][Full Text] [Related]
27. Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.
Lages CS; Lewkowich I; Sproles A; Wills-Karp M; Chougnet C
Aging Cell; 2010 Oct; 9(5):785-98. PubMed ID: 20653631
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
29. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation.
Pfistershammer K; Klauser C; Pickl WF; Stöckl J; Leitner J; Zlabinger G; Majdic O; Steinberger P
Eur J Immunol; 2006 May; 36(5):1104-13. PubMed ID: 16598819
[TBL] [Abstract][Full Text] [Related]
30. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
Martin-Orozco N; Wang YH; Yagita H; Dong C
J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
[TBL] [Abstract][Full Text] [Related]
31. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.
Matsumoto K; Inoue H; Nakano T; Tsuda M; Yoshiura Y; Fukuyama S; Tsushima F; Hoshino T; Aizawa H; Akiba H; Pardoll D; Hara N; Yagita H; Azuma M; Nakanishi Y
J Immunol; 2004 Feb; 172(4):2530-41. PubMed ID: 14764726
[TBL] [Abstract][Full Text] [Related]
32. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.
Brandl C; Ortler S; Herrmann T; Cardell S; Lutz MB; Wiendl H
PLoS One; 2010 May; 5(5):e10800. PubMed ID: 20520738
[TBL] [Abstract][Full Text] [Related]
33. Differential binding properties of B7-H1 and B7-DC to programmed death-1.
Youngnak P; Kozono Y; Kozono H; Iwai H; Otsuki N; Jin H; Omura K; Yagita H; Pardoll DM; Chen L; Azuma M
Biochem Biophys Res Commun; 2003 Aug; 307(3):672-7. PubMed ID: 12893276
[TBL] [Abstract][Full Text] [Related]
34. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
35. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.
Jurado JO; Alvarez IB; Pasquinelli V; Martínez GJ; Quiroga MF; Abbate E; Musella RM; Chuluyan HE; García VE
J Immunol; 2008 Jul; 181(1):116-25. PubMed ID: 18566376
[TBL] [Abstract][Full Text] [Related]
36. siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.
Breton G; Yassine-Diab B; Cohn L; Boulassel MR; Routy JP; Sékaly RP; Steinman RM
J Clin Immunol; 2009 Sep; 29(5):637-45. PubMed ID: 19562472
[TBL] [Abstract][Full Text] [Related]
37. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
[TBL] [Abstract][Full Text] [Related]
38. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Butte MJ; Keir ME; Phamduy TB; Sharpe AH; Freeman GJ
Immunity; 2007 Jul; 27(1):111-22. PubMed ID: 17629517
[TBL] [Abstract][Full Text] [Related]
39. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C; Gajewski TF; Mackensen A
Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
[TBL] [Abstract][Full Text] [Related]
40. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
